Direct reprogramming of fibroblasts into skeletal muscle or neural lineages by using a single transcription factor with or without MyoD transactivation domain

Direct reprogramming of fibroblasts into skeletal muscle or neural lineages by using a single transcription factor with or without MyoD transactivation domain

Nandkishore R Belur, Atsushi Asakura, Tomohide Takaya.

Stem Cell institute, Paul & Sheila Wellstone Muscular Dystrophy Center, Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.

The Annual Conference and Retreat of Institute for Engineering in Medicine 2014 (Minneapolis, USA), 2014/09/22 (Poster).

Abstract

The generation of induced pluripotent stem cells (iPSCs) from somatic cells has opened new doors for regenerative medicine by overcoming the ethical concerns surrounding embryonic stem (ES) cell research. However, iPSC technology presents several safety concerns, such as the potential risk of tumor formation, that have caused apprehension for use of iPSCs in humans. One such approach that can circumvent the problem is "direct reprogramming" which can bypass the iPSC or pluripotent stage and obtain tissue-specific cell types from somatic cells. In this study, we examined whether an important transcription factor involved in myogenesis (Pax3) or neurogenesis (NeuroD1) alone can directly reprogram the mouse embryonic fibroblasts (MEFs) into myogenic or neurogenic lineages, respectively. In addition, we created fusion transcription factors (Pax3 or NeuroD1) with the potent MyoD transactivation domain (MDA) that could facilitate radical acceleration of reprogramming into the desired cell type through chromatin modification compared to wild-type factors. Here, we showed that Pax3 can reprogram MEFs towards a myogenic lineage and that MDA-Pax3 further enhances this myogenic reprogramming event. In addition, ectopic expression of NeuroD1 and MDA-NeuroD1 is able to induce neurogenic genes in MEFs, suggesting the partial neurogenic conversion of MEFs. These data suggest that single gene transduction such as Pax3 or NeuroD1 will become a feasible therapeutic approach for neuro- and muscle degenerative diseases, respectively.